These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 23974270)
1. Reversal of a dabigatran overdose: what are possible options? Ratanapo S; Ungprasert P; Srivali N; Cheungpasitporn W; Bischof EF Am J Med Sci; 2013 Sep; 346(3):259. PubMed ID: 23974270 [No Abstract] [Full Text] [Related]
2. Dabigatran and bleeding: still an emergent situation? Van Heukelom J; Lal Y Am J Med Sci; 2013 Sep; 346(3):259. PubMed ID: 23698156 [No Abstract] [Full Text] [Related]
3. [Dabigatran and emergency operation on a peritonitis patient]. Ilmakunnas M; Louhimo J; Lassila R Duodecim; 2012; 128(7):753-7. PubMed ID: 22612026 [TBL] [Abstract][Full Text] [Related]
4. Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. Getta B; Muller N; Motum P; Hsu D; Zebeljan D; Rosenfeld D Br J Haematol; 2015 May; 169(4):603-4. PubMed ID: 25425051 [No Abstract] [Full Text] [Related]
5. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Lillo-Le Louët A; Wolf M; Soufir L; Galbois A; Dumenil AS; Offenstadt G; Samama MM Thromb Haemost; 2012 Sep; 108(3):583-5. PubMed ID: 22782645 [No Abstract] [Full Text] [Related]
6. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Warkentin TE; Margetts P; Connolly SJ; Lamy A; Ricci C; Eikelboom JW Blood; 2012 Mar; 119(9):2172-4. PubMed ID: 22383791 [No Abstract] [Full Text] [Related]
7. Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage. Aron JL; Gosselin R; Moll S; Arkin CF; Mantha S J Thromb Thrombolysis; 2014; 37(2):76-9. PubMed ID: 23519385 [No Abstract] [Full Text] [Related]
8. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study. Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158 [TBL] [Abstract][Full Text] [Related]
15. The importance of postapproval data for dabigatran. Redberg RF JAMA Intern Med; 2015 Jan; 175(1):25. PubMed ID: 25365377 [No Abstract] [Full Text] [Related]
16. Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding. Wong H; Keeling D Br J Haematol; 2014 Jul; 166(1):152-3. PubMed ID: 24617554 [No Abstract] [Full Text] [Related]
17. Bleeding risk with dabigatran in the frail elderly. Harper P; Young L; Merriman E N Engl J Med; 2012 Mar; 366(9):864-6. PubMed ID: 22375994 [No Abstract] [Full Text] [Related]
18. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P; Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130 [TBL] [Abstract][Full Text] [Related]
19. The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa. Htun KT; McFadyen J; Tran HA Ann Hematol; 2014 Oct; 93(10):1785-6. PubMed ID: 24584995 [No Abstract] [Full Text] [Related]